Abstract:BACKGROUND:Reducing mutant huntingtin (mHTT) in neurons may be a therapy for Huntington's disease (HD). Elevating NUB1 protein reduced mHTT levels in cell and fly models of HD through a proteasome dependent mechanism.OBJECTIVE:To examine the effects of augmenting NUB1 in HD mouse striatum on mHTT levels.METHODS:Striata of HDQ175/Q7 mice were injected at 3 months of age with recombinant AAV2/9 coding for NUB1 or GFP under the control of the neuron specific human synapsin 1 promoter and examined 6 months post-injection for levels of huntingtin, the striatal markers DARPP32 and PDE10A, the astrocyte marker GFAP, and the autophagy and mHTT aggregate marker P62 using immunolabeling of brain sections and Western blot assay of striatal subcellular fractions.RESULTS:By Western blot human HD brain had only one of the two variants of NUB1 present in human control brain. In striatum of WT and HD mice NUB1 was localized in medium size neurons and enriched in the nucleus of large neurons. In the striatum of NUB1 injected HD mice, there was widespread neuronal distribution of exogenous NUB1 labeling and protein levels were ∼2.5-fold endogenous levels. DARPP32 and GFAP distribution and levels were unchanged but PDE10A levels were lower in crude homogenates and P62 was increased in nuclear enriched P1 fractions. Elevating NUB1 did not change levels of full-length mHTT or the number and size of mHTT (S830) positive nuclear inclusions.CONCLUSION:Findings suggest that increasing NUB1 protein in striatal neurons of HDQ175/Q7 mice in vivo may be relatively safe but is ineffective in reducing mHTT. Increased NUB1 expression in HD striatum alters PDE10A and P62 which are known to be influenced by mHTT.

NUB1 Suppression of Huntington Toxicity: Mechanistic Insights

Identification of Nub1 As A Suppressor of Mutant Huntingtin Toxicity Via Enhanced Protein Clearance

HAP40 is a conserved central regulator of Huntingtin and a specific modulator of mutant Huntingtin toxicity

Effects of Exogenous Nub1 Expression in the Striatum of Hdq175/Q7 Mice

Inhibiting the ubiquitin-proteasome system leads to preferential accumulation of toxic N-terminal mutant huntingtin fragments.

Suppression of MAPK11 or HIPK3 Reduces Mutant Huntingtin Levels in Huntington's Disease Models

Subcellular Clearance and Accumulation of Huntington Disease Protein: A Mini-Review.

Nucleolar stress controls mutant Huntington toxicity and monitors Huntington’s disease progression

Essential sequence of the N-terminal cytoplasmic localization-related domain of huntingtin and its effect on huntingtin aggregates

Huntington's Disease: Molecular Basis of Pathology and Status of Current Therapeutic Approaches.

Huntington’s Disease: Complex Pathogenesis and Therapeutic Strategies

Dysregulation of C/EBPalpha by Mutant Huntingtin Causes the Urea Cycle Deficiency in Huntington's Disease.

Peripheral sequestration of huntingtin delays neuronal death and depends on N-terminal ubiquitination

Complex Pathogenesis and Therapeutic Strategies

Inhibition of Neurite Outgrowth and Promotion of Cell Death by Cytoplasmic Soluble Mutant Huntingtin Stably Transfected in Mouse Neuroblastoma Cells

Enhancement of Brain-Type Creatine Kinase Activity Ameliorates Neuronal Deficits in Huntington's Disease

Ubiquitin-Activating Enzyme Activity Contributes to Differential Accumulation of Mutant Huntingtin in Brain and Peripheral Tissues

An insight into allele-selective approaches to lowering mutant huntingtin protein for Huntington's disease treatment

Context-dependent Dysregulation of Transcription by Mutant Huntingtin

HAP40 Modulates Mutant Huntingtin Aggregation and Toxicity in Huntington’s Disease Mice